… of biomarkers rather than a single analyte will have the most utility for the diagnosis of AD,
predicting which NC individuals and which subjects with MCI will progress to AD, as well as …

The Alzheimer's Disease Neuroimaging Initiative (ADNI) beginning in October 2004, is a 6-year
research project that studies changes of cognition, function, brain structure and function, …

OBJECTIVE: Minimum therapeutic doses of paroxetine and citalopram produce 80%
occupancy for the serotonin (5-HT) transporter (5-HTT). The authors used [ 11 C]DASB positron …

Objective: To compare the diagnostic accuracy of CSF biomarkers and amyloid PET for
diagnosing early-stage Alzheimer disease (AD). Methods: From the prospective, longitudinal …

In this study, we review progress by the Penn Biomarker Core in the Alzheimer's Disease
Neuroimaging Initiative (ADNI) toward developing a pathological cerebrospinal fluid (CSF) and …

… The following chapters of this book will review these issues in depth, beginning with an
examination of the motivations and capabilities of the terrorist organizations that might seek to …

A recently identified variant within the fat mass and obesity-associated (FTO) gene is carried
by 46% of Western Europeans and is associated with an ~1.2 kg higher weight, on average, …

The close correlation between abnormally low pre-mortem cerebrospinal fluid (CSF)
concentrations of amyloid-β1-42 (Aβ 1–42 ) and plaque burden measured by amyloid imaging as …

Treatment effects are often evaluated by comparing change over time in outcome measures;
however, valid analyses of longitudinal data can be problematic, particularly if some data …

The ε4 allele of the apolipoprotein E (APOE) gene is the major genetic risk factor for
Alzheimer’s disease (AD), but limited work has suggested that APOE genotype may modulate …